Dopaminergic pharmacology and antioxidant properties of pukateine, a natural product lead for the design of agents increasing dopamine neurotransmission

General Pharmacology

Volumn 32, Issue 3, 1999, Pages 373-379

  Dajas Bailador, Federico A ^a   Asencio, Marcelo ^b   Bonilla, Carolina ^a   Scorza, Ma Cecilia ^a   Echeverry, Carolina ^a   Reyes Parada, Miguel ^a   Silveira, Rodolfo ^a   Protais, Philippe ^c   Russell, Graeme ^d   Cassels, Bruce K ^b   Dajas, Federico ^a  

^a INSTITUTO DE INVESTIGACIONES BIOLÓGICAS CLEMENTE ESTABLE   (Uruguay)

^b UNIVERSITY OF CHILE   (Chile)

^c UNIVERSITÉ DE ROUEN   (France)

^d THE NEW ZEALAND INSTITUTE FOR PLANT AND FOOD RESEARCH LIMITED   (New Zealand)

Author keywords

Aporphines; Brain dopamine; Dopamine receptor binding; Lipid peroxidation; Oxidative stress; Parkinson disease; Pukateine

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMINE OXIDASE (FLAVIN CONTAINING); ANTIOXIDANT; APOMORPHINE; APORPHINE DERIVATIVE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; OXIDOPAMINE; RACLOPRIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BINDING SITE; BRAIN MITOCHONDRION; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINERGIC SYSTEM; DRUG RECEPTOR BINDING; LIPID PEROXIDATION; MALE; MICRODIALYSIS; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIOXIDANTS; APORPHINES; CENTRAL NERVOUS SYSTEM; DOPAMINE; DOPAMINE AGENTS; LIPID PEROXIDATION; MALE; MICRODIALYSIS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTIC TRANSMISSION;

EID: 0033046305     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(98)00210-9     Document Type: Article

References (42)

1. Ambani L.M., Van Woert M.H., Murphy S. Brain peroxidase and catalase in Parkinson's disease. Arch Neurol. 32:1975;114-118.
2. Bannach R., Valenzuela A., Cassels B.K., Núñez-Vergara L.J., Speisky H. Cytoprotective and antioxidant effects of boldine on tert-butyl hydroperoxide-induced damage to isolated hepatocytes. Cell Biol Toxicol. 12:1996;89-100.
3. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci. 20:1973;415-455.
4. Buege J.A., Aust S.D. Microsomal lipid peroxidation. Methods Enzymol. 52:1978;302-310.
5. Cassels B.K., Asencio M., Conget P., Speisky H., Videla L.A., Lissi E.A. Structure-antioxidative activity relationships in benzylisoquinoline alkaloids. Pharmac Res. 31:1995;103-107.
6. 3H]-raclopride binding sites. J Nat Prod. 55:1992;1281-1286.
7. Dajas-Bailador F., Costa G., Emmett S., Bonilla C., Dajas F. Acetylcholinesterase inhibitors block acetylcholine-evoked release of dopamine in rat striatum, in vivo. Brain Res. 722:1996;12-18.
8. Dexter D.T., Wells F.R., Lees A.J., Agid F., Agid Y., Jenner P., Marsden C.D. Increased nigral iron content and alterations in other metal ions ocurring in brain in Parkinson's disease. J Neurochem. 52:1989;1830-1836.
9. Dexter D.T., Carayon A., Vidailhet M., Ruberg N., Agid F., Agid Y., Lees A.J., Wells F.R., Jenner P., Marsden C.D. Decreased ferritin levels in brain in Parkinson's disease. J Neurochem. 55:1990;16-20.
10. Dexter D.T., Brooks D.J., Harding A.E., Burn D.J., Muller D.P., Goss-Sampson N.A., Jenner P.G., Marsden C.D. Nigrostriatal function in vitamin E deficiency. clinical, experimental and positron emission tomographic studies Ann Neurol. 35:1994;298-303.
11. Ebadi M., Srinivasan S.K., Baxi M.D. Oxidative stress and antioxidant therapy in Parkinson's disease. Prog Neurobiol. 48:1996;1-19.
12. Golbe L.I., Lieberman A.N., Muenter M.D., Ahlskog J.E., Gopinathan G., Neophytides A.N., Foo S.H., Duvoisin R. Deprenyl in the treatment of symptom fluctuation in advanced Parkinson's disease. Clin Neuropharmac. 2:1988;45-55.
13. 3H] spiroperidol binding and rotational behavior in unilateral 6-OHDA lesioned rats. Brain Res. 211:1981;285-292.
14. Hirsch E.C. Nerve cell death in Parkinson's disease. Martignoni E., Giovannini P. New advances in Parkinson's disease and other extrapyramidal disorders. 1994;7-14 Smith Gordon, Great Britain.
15. Jenner P. What process causes nigral cell death in Parkinson's disease? Neurol Clin. 10:1992;387-403.
16. McPherson G. Analysis of radioligand binding experiments. a collection of computer programs for the IBM PC J Pharmac Methods. 14:1985;213-218.
17. Mizuno Y., Iwata M., Kanazawa I., Nakanishi T., Yanagisawa N. Dopamine agonists as adjuvants. monotherapy and early combination therapy Rinne U.K., Nagatsu T., Horowski R. Parkinson's disease, from basic research and early diagnosis to long term treatments. 1991;314-325 International Workshop Berlin, Berlin Medicom Europe, Berlin.
18. Neumeyer J.L. Synthesis and structure-activity relationships of aporphines as dopamine receptor agonists and antagonists. Phillipson J.D., Roberts M.F., Zenk M.H. The chemistry and biology of isoquinoline alkaloids. 1985;146-170 Springer-Verlag, Berlin, Heidelberg.
19. Neumeyer J.L., Lal S., Baldessarini R.J. Historical highlights of the chemistry, pharmacology and early clinical uses of apomorphine. Gessa G.L., Corsini G.U. Apomorphine and other dopaminomimetics. 1981;1-17 Raven Press, New York.
20. Neumeyer J.L., Guan J.H., Niznik H.B., Dumbrille-Ross A., Seeman P., Padmanabhan S., Elmaleh D.R. Novel photoaffinity label for the dopamine D2 receptor. synthesis of 4-azido-5-iodo-2-methozy-N-[1-(phenylmethyl)-4-piperidinyl] benzamide (iodoazidoclebopride, IAC) and the corresponding 125I-labeled analogue (125IAC) J Med Chem. 28:1985;405-407.
21. Olanow C., Arendash G. Metals and free radicals in neurodegeneration. Curr Opin Neurol. 7:1994;548-558.
22. Paxinos, G., Watson, G., 1986. The rat brain in stereotaxic coordinates (2nd ed.), Academic Press, Australia.
23. Perry T.L., Yang V.W. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett. 67:1986;269-274.
24. Protais P., Bonnett J.-J., Costentin J., Schwartz J.C. Rat climbing behaviour elicited by stimulation of cerebral dopamine receptors. Naunyn-Schmiedeberg's Arch Pharmac. 325:1984;93-101.
25. 3H]-raclopride binding sites. Experientia. 48:1992;27-30.
26. 3H]-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 58:1995;1475-1484.
27. Reyes-Parada M., Scorza M.C., Silveira R., Dajas F., Costa G., Tipton K.F., Cassels B.K. Monoamine oxidase inhibitory effects of some 4-aminophenethylamine derivatives. Biochem Pharmac. 8:1994;1365-1371. a.
28. Reyes-Parada M., Scorza M.C., Silveira R., Dajas F., Cassels B.K. 4-Dimethylamino-phenethylamine, a sensitive, specific, electrochemically detectable monoamine oxidase-B substrate. Life Sci. 25:1994;1955-1963. b.
29. Rinne U.K. Problems associated with long term levodopa treatment of Parkinson's disease. Acta Neurol Scand. 68(suppl. 95):1983;19-26.
30. Rinne U.K. Dopamine agonists in the treatment of early Parkinson's disease. Caraceni T., Nappi G. Focus on Parkinson's disease. 1991;203-208 Masson S.P.A, Milan.
31. Scorza, M.C., Carrau, C., Silveir, R., Zapata-Torres, G., Cassels, B.K., Reyes-Parada, M., in press. Monoamine oxidase inhibitory properties of some methozylated and alkylthio amphetamine derivatives. Biochem Pharmac.
32. Sethy V.H., Wu H., Oostveen J.O., Hall E.D. Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats. Brain Res. 754:1997;181-186.
33. Sheppard H., Brughardt C.R. The dopamine-sensitive adenylate cyclase of the rat caudate nucleus. 3. The effects of aporphines and protoberberines Biochem Pharmac. 27:1978;1113-1116.
34. Simonian N.A., Coyle J.T. Oxidative stress in neurodegenerative diseases. Annu Rev Pharmac Toxicol. 36:1996;83-106.
35. Speisky H., Cassels B.K., Lissi E.A., Videla L.A. Antioxidant properties of the alkaloid boldine in systems undergoing lipid peroxidation and enzyme inactivation. Biochem Pharmac. 41:1991;1575-1582.
36. Tetrud J.W., Langston J.W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science. 245:1989;519-522.
37. The Parkinson Study Group Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 328:1993;176-183.
38. Ungerstedt U. Postsynaptic supersensitivity after 6-OHDA induced degeneration of the nigrostriatal dopaminergic system. Acta Physiol Scand. 367:1971;69-93.
39. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-OHDA lesions of the nigrostriatal dopamine system. Brain Res. 24:1970;485-493.
40. Urzúa A., Cassels B.K. Additional alkaloids from Laurelia philippiana and L. novae-zelandiae. Phytochemistry. 21:1982;773-776.
41. + toxicity by deprenyl (selegiline). In: Chiueh, C.C., Gilbert, D.L., Colton, C.A. (Eds.), The neurobiology of NO· and OH·. Ann N Y Acad Sci 738, 214-221.
42. Yahr M.D. Evaluation of long term therapy in Parkinson's disease. mortality and therapeutic efficacy Brikmayer W., Hornykiewicz O. Advances in Parkinsonism. 1976;435-443 Editiones Roche, Basel.